Besides ESS and oral and intranasal corticosteroids, the mainstays of treatment for patients with CRSwNP involve other medical management/medication, including antibiotics and antifungals, antihistamines, and monoclonal antibodies targeting interleukins, such as IL-4, IL-5, and IL-13, or IgE (benralizumab, dupilumab, mepolizumab, and omalizumab), among others with varying efficacy [9,21,43,45,46]. Here, IGHE is linked to chronic rhinosinusitis with nasal polyps.